Sofosbuvir is a direct-acting antiviral agent used to treat specific hepatitis C virus (HCV) infections in combination with other antiviral agents. HCV is a single-stranded RNA virus that is categorized into nine distinct genotypes, with genotype 1 being the most common in the United States, and affecting 72% of all chronic HCV patients.
- Mechanism
- Curator reviewed
Sofosbuvir is nucleotide analog inhibitor, which specifically inhibits HCV NS5B (non-structural protein 5B) RNA-dependent RNA polymerase. Following intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), sofosbuvir incorporates into HCV RNA by the NS5B polymerase and acts as a chain terminator [synthesis, A7533]. More specifically, Sofosbuvir prevents HCV viral replication by binding to the two Mg2+ ions present in HCV NS5B polymerase's GDD active site motif and preventing further replication of HCV genetic material.
- Primary indication
- Sofosbuvir is used in combination therapy with other antiviral medications to treat chronic hepatitis C virus (HCV) infected patients with HCV genoptypes 1-6, and to treat HCV and HIV co-infected patients.Curator reviewed · 30 structured indications
- Formula / weight
- C22H29FN3O9P · 529.458 g/mol (avg)
- First approval
- Canada, 2013 · United States, 2013 · European Union, 2016
- Code names
- GI-7977 · GS-331007 · GS-461203 · GS-7977 · PSI-7977
- Brand names
Resolves to
TTZHDVOVKQGIBA-IQWMDFIBSA-NSMILESCC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1What you can answer from here — as of May 03, 2025
Which drugs share a target with Sofosbuvir, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account